Haemokinesis Listed by rhysida Ransomware Group: Ransomware Claim — What’s Alleged & What To Do

In June 2023, the name Haemokinesis appeared on a ransomware group’s leak site, raising immediate practical questions for anyone whose information might sit in the company’s systems. The listing claimed that internal files had been taken and made available, yet the number of people affected remains unknown and the precise contents of those files have not been independently detailed in public reporting. For customers, partners, laboratory contacts, or staff, the core concern is straightforward: whether personal, professional, or commercial data tied to immunohematology work may have been exposed and what that exposure could mean in ordinary life.

Public detail is limited. What is known comes chiefly from the group’s own claim and a brief accompanying description of the organisation. No confirmed count of affected individuals, no verified inventory of every file type, and no independent timeline of the intrusion have been published alongside the listing. That scarcity of confirmed fact is itself part of the picture people must navigate.

Inside the incident

On or around 5 June 2023, Haemokinesis was listed by the rhysida ransomware group. The group stated that internal files had been exfiltrated in a ransomware attack and asserted that “Documents 100% all files was uploaded to public access.” The listing presented the material as available to “data hunters.” Beyond that claim, the method of initial access, the duration of any presence inside the network, the exact volume of data, and any ransom demand or negotiation outcome remain undisclosed in the available record.

No public confirmation has established whether the claimed upload was complete, partial, or accurate, nor has an official statement from Haemokinesis detailing the incident been incorporated into the facts at hand. The number of people affected is recorded as unknown. The incident is therefore best understood as a claimed ransomware event involving alleged exfiltration of internal files, reported via the group’s leak site on the date noted, with most operational particulars still unconfirmed.

Who is rhysida?

Rhysida is a ransomware operation that became publicly visible in 2023. Like other groups in the same period, it has typically combined encryption of victim systems with the theft of data, then used dedicated leak sites to pressure organisations by threatening or carrying out publication. The group’s listings often include short descriptions of the victim and claims about the percentage of data allegedly taken or released. Rhysida has been associated with attacks across multiple sectors and geographies; its public persona relies on the double-extortion model rather than encryption alone.

In this case, the appearance of Haemokinesis on the rhysida site constitutes the group’s claim. Nothing in the provided facts independently verifies the volume, completeness, or specific sensitivity of the material the group said it uploaded. Readers should treat the leak-site statements as assertions by the threat actor, not as established findings, unless and until corroborated by the organisation or by competent investigators.

Haemokinesis and its sector

Haemokinesis specialises in research and development, laboratory systems, and the sales and distribution of immunohematology products. Immunohematology concerns blood typing, compatibility testing, and related laboratory work that supports transfusion medicine and diagnostic services. Organisations in this space commonly interact with hospitals, blood services, research partners, distributors, and regulatory frameworks that govern medical devices and laboratory reagents.

A breach affecting such an organisation is consequential because the sector handles technical, commercial, and sometimes personal data linked to healthcare supply chains. Even when clinical patient records are not the primary holdings, internal files can include customer and supplier details, research materials, quality documentation, pricing, and employee information. Disruption or exposure in this niche can affect trust, contractual relationships, and the secure handling of information that underpins laboratory and distribution operations.

What data was at risk

The facts name the exposed material as internal files exfiltrated in a ransomware attack. The rhysida listing further claimed that documents representing “100%” of files had been uploaded to public access. No more granular inventory—such as specific categories of personal data, financial records, or research datasets—has been confirmed in the available record.

Organisations of this kind typically hold a mix of corporate documents, customer and distributor contact information, product and regulatory files, research and development materials, and employee-related records. Whether any of those categories were present in the claimed exfiltration, and in what volume or sensitivity, is unconfirmed. Exact contents therefore remain undisclosed; the only firm public description is the threat actor’s assertion of internal files made available.

What's at stake

For individuals, the practical risks depend on what was actually taken. If contact details, identity documents, or employment information were included, possible outcomes include unwanted contact, phishing attempts that reference the company, or attempts to reuse credentials elsewhere. If commercial or research files were involved, partners and customers may face competitive or contractual exposure. Because the number of people affected is unknown and the file list is unverified, these remain potential rather than proven harms for any given person.

For Haemokinesis, the stakes include operational disruption from the ransomware event itself, reputational damage from the public listing, possible regulatory or contractual notifications, and the cost of investigation and remediation. The sector’s reliance on trust in product quality and supply integrity means that even unconfirmed claims of data exposure can prompt scrutiny from customers and partners. None of this establishes negligence; it simply describes the ordinary consequences that follow when a ransomware group publicly names an organisation and alleges data theft.

Were you affected?

If you have a past or present relationship with Haemokinesis—as a customer, supplier, research contact, or employee—consider practical steps. Monitor accounts and inboxes for unexpected messages that reference the company or request urgent action. Review financial and credit activity if you ever shared identity or payment details. Change passwords that may have been reused across work and personal services, and enable multi-factor authentication where available. Preserve any official notice you receive from the organisation rather than relying solely on third-party claims.

Public detail on this incident remains limited, so confirmation of personal exposure may take time or may never be fully itemised. Readers can run a free exposure scan of their email address to check whether their information has already surfaced in known breach data sets. That check does not prove involvement in this specific event, but it offers a concrete starting point for understanding whether credentials or personal details appear in wider circulating collections.

AICompiled with AI assistance from public sources and published under our editorial standards.